Tender Details

Country: USA
Summary: Development Of Medications To Prevent And Treat Substance Use Disorders And Overdose (Ug3/Uh3 - Clinical Trial Optional)
UST Ref No: 112684100
Deadline: 11 Aug 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: PAR-25-329
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
The Purpose Of This Notice Of Funding Opportunity (Nofo) Is To Support The Discovery And Development Of Medications To Prevent And Treat Substance Use Disorders (Suds) And Overdose. The Ug3/Uh3 Phase Innovation Awards Cooperative Agreement Involves 2 Phases. The Ug3 Is To Support A Project With Specific Milestones To Be Accomplished By The End Of The 2-Year Period. The Uh3 Is To Provide Funding For 3 Years To A Project That Successfully Completed The Milestones Set In The Ug3. Ug3 Projects That Have Met Their Milestones Will Be Administratively Considered By Nida And Prioritized For Transition To The Uh3 Phase. Investigators Responding To This Nofo Must Address Both Ug3 And Uh3 Phases. Application May Include Preclinical Or Clinical Research Studies That Will Have High Impact And Quickly Yield The Necessary Results To Advance Closer To Fda Approval Medications That Are Safe And Effective To Prevent And Treat Suds And Overdose. The Compounds To Be Evaluated Can Be Small Molecules, Biologics, Or Natural Products. They Can Be Tested In Pre-Clinical Models And/Or For The Clinical Manifestations Of Suds Such As Withdrawal, Craving, Relapse, Or Overdose. Applications May Focus On The Development Of New Chemical Entities, New Formulations Of Marketed Medications Available For Other Indications, Or Combinations Of Medications That Hold Promise For The Treatment Of Suds And Overdose. Through This Nofo, Nida Seeks To Fast-Track The Discovery And Development Of Medications To Prevent An...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Development Of Medications To Prevent And Treat Substance Use Disorders And Overdose (Ug3/Uh3 - Clinical Trial Optional) - USA Tender

The NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Development Of Medications To Prevent And Treat Substance Use Disorders And Overdose (Ug3/Uh3 - Clinical Trial Optional). This tender is published on USARFP under UST Ref No: 112684100 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-08-11.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.